AbbVie ABBV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $697M-45.9% | $1.82B— | $188M-88.0% | $941M-31.5% | $1.29B-6.0% | ||
| $444M+8.3% | $157M-4.3% | $209M+15.5% | $179M-17.9% | $410M+17.8% | ||
| $137M+589% | -$385M+49.8% | —— | -$272M-1,600% | -$28M+92.8% | ||
| -$87M-106% | —— | $156M— | $17M— | $1.48B+111% | ||
| $184M+18.7% | $25M-80.5% | $0-100% | $56M+7.7% | $155M+107% | ||
| -$1.59B-129% | —— | $1.73B+548% | —— | -$696M-292% | ||
| $3.83B+134% | $5.22B-26.0% | $7.02B+29.0% | $5.15B+127% | $1.64B-59.5% | ||
| $265M+12.8% | $329M+13.1% | $381M+53.0% | $269M+11.6% | $235M+21.8% | ||
| $0-100% | —— | —— | —— | $204M-97.8% | ||
| -$574M+21.9% | -$1.46B+21.9% | -$3.26B+60.5% | -$1.18B-7.2% | -$735M+92.3% | ||
| $3.09B+5.5% | $2.91B+5.8% | $2.91B+5.8% | $2.91B+5.8% | $2.93B+5.5% | ||
| $1.49B+54.9% | $3M-99.2% | $4M-76.5% | $12M+33.3% | $961M-27.4% | ||
| $7.99B+100% | —— | —— | —— | $3.99B-73.3% | ||
| $919M+173% | -$4.17B+39.3% | -$4.59B— | -$2.71B— | -$1.26B-112% | ||
| -$12M-233% | $11M+124% | —— | $30M+433% | $9M+150% | ||
| $4.16B+1,293% | -$400M+76.9% | -$838M+85.7% | $1.29B+126% | -$349M-107% | ||
| —— | $750.5M+6.8% | $750.5M+6.8% | $750.5M+6.8% | $750.5M+6.8% | ||
| $150M+121% | —— | -$319M-202% | -$21M-154% | -$729M-5,975% | ||
| $22M+229% | $9M— | $90M+309% | -$79M-495% | -$17M-152% | ||
| $722M+31.5% | $681M+26.3% | $776M+33.8% | $859M+77.1% | $549M+40.4% | ||
| $1.75B-5.9% | $1.78B-5.9% | $1.9B0.0% | $1.9B0.0% | $1.86B-1.7% | ||
| $2.39B+57.2% | $1.41B+404% | $776M-42.8% | $2.8B+89.4% | $1.52B+130% | ||
| $188M+3.9% | $203M-1.5% | $192M+0.5% | $186M+1.1% | $181M-1.1% | ||
| -$81M-121% | —— | -$411M— | -$1.38B+25.0% | $378M0.0% | ||
| $150M-76.1% | $658M— | —— | —— | $628M+321% | ||
| $22M+229% | $9M— | $90M+309% | -$79M-495% | -$17M-152% | ||
| $43M+213% | $1M+101% | $77M+2,667% | -$11M-320% | -$38M-733% | ||
| $266M-20.4% | $1.16B-35.2% | $2.8B+1,308% | $940M+11.5% | $334M+75.8% | ||
| $2B— | $791M— | $2.01B— | $0-100% | $0-100% | ||
| $2M-97.0% | —— | $37M+15.6% | —— | $67M+179% | ||
| -$499M-131% | —— | —— | —— | $1.59B— | ||
| $0-100% | $8M-99.9% | $9M-97.8% | $3.75B+12.2% | $3.03B+2,838% | ||
| $2B— | —— | —— | —— | $0— | ||
| $3.56B+155% | $4.89B-27.6% | $6.64B+27.8% | $4.88B+141% | $1.4B-63.6% | ||
| $3.56B+155% | $4.89B-27.6% | $6.64B+27.8% | $4.88B+141% | $1.4B-63.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbbVie generate?
- AbbVie (ABBV) generated $21.2B in operating cash flow over the trailing twelve months.
- What is AbbVie's free cash flow?
- After $1.2B of capital expenditures, AbbVie's free cash flow was $20.0B over the trailing twelve months, up 29.9% year over year.
- Where does AbbVie's cash flow data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
